2/6
07:07 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Ionis Pharmaceuticals (NASDAQ:IONS) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
1/30
06:01 am
ions
This 11-year-old has battled a rare disease for years — a breakthrough drug helped deliver relief [CNBC]
Low
Report
This 11-year-old has battled a rare disease for years — a breakthrough drug helped deliver relief [CNBC]
1/28
08:03 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $95.00 price target on the stock.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $95.00 price target on the stock.
1/24
05:09 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
07:00 am
ions
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
Low
Report
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
1/13
02:41 pm
ions
Assessing Ionis Pharmaceuticals (IONS) Valuation After A Strong 1 Year Shareholder Return [Yahoo! Finance]
Low
Report
Assessing Ionis Pharmaceuticals (IONS) Valuation After A Strong 1 Year Shareholder Return [Yahoo! Finance]
1/12
07:00 am
ions
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
Low
Report
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
1/8
06:16 am
ions
GSK, Ionis claim study success for RNA-based hepatitis B drug [Yahoo! Finance]
Medium
Report
GSK, Ionis claim study success for RNA-based hepatitis B drug [Yahoo! Finance]
1/7
03:53 am
ions
GSK Reports 'Positive' Phase 3 Results From Chronic Hepatitis B Studies [Yahoo! Finance]
Low
Report
GSK Reports 'Positive' Phase 3 Results From Chronic Hepatitis B Studies [Yahoo! Finance]
1/7
02:15 am
ions
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
Low
Report
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
1/6
07:05 am
ions
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
1/5
08:42 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
12/17
07:06 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
12/15
11:07 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) was given a new $100.00 price target on by analysts at Leerink Partners.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) was given a new $100.00 price target on by analysts at Leerink Partners.
12/15
04:31 am
ions
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe [Yahoo! Finance]
Low
Report
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe [Yahoo! Finance]
12/9
01:15 pm
ions
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Bank of America Corporation from $86.00 to $97.00. They now have a "buy" rating on the stock.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Bank of America Corporation from $86.00 to $97.00. They now have a "buy" rating on the stock.
12/3
11:14 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
12/2
07:00 am
ions
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
Low
Report
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
12/1
11:37 am
ions
Ionis Pharmaceuticals (IONS): Valuation Insights Following FDA Breakthrough Therapy Status for Olezarsen [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals (IONS): Valuation Insights Following FDA Breakthrough Therapy Status for Olezarsen [Yahoo! Finance]
12/1
09:22 am
ions
Ionis Pharmaceuticals (IONS) Up 5.4% After EMA Nod and $700M Raise—Has the Bull Case Changed? [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals (IONS) Up 5.4% After EMA Nod and $700M Raise—Has the Bull Case Changed? [Yahoo! Finance]
12/1
07:00 am
ions
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
Low
Report
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
11/18
09:24 am
ions
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer [Yahoo! Finance]
Low
Report
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer [Yahoo! Finance]
11/17
06:35 am
ions
Biogen acquires Alcyone to boost CNS drug delivery [Yahoo! Finance]
Low
Report
Biogen acquires Alcyone to boost CNS drug delivery [Yahoo! Finance]
11/15
06:41 am
ions
What Recent Clinical Trial Updates Mean for Ionis Pharmaceuticals Stock Valuation in 2025 [Yahoo! Finance]
Low
Report
What Recent Clinical Trial Updates Mean for Ionis Pharmaceuticals Stock Valuation in 2025 [Yahoo! Finance]
11/14
07:00 am
ions
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
Medium
Report
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)